Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. - Wikidata - awgldk - TriplyDB

Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.

Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.

http://www.wikidata.org/entity/Q51485069

about

New advances in the treatment of generalized lipodystrophy: role of metreleptin Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals Leptin applications in 2015: what have we learned about leptin and obesity?Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies Leptin revisited: its mechanism of action and potential for treating diabetes.Obesity as an effect modifier of the association between leptin and diabetic kidney disease.Dietary combination of sucrose and linoleic acid causes skeletal muscle metabolic abnormalities in Zucker fatty rats through specific modification of fatty acid composition.Does leptin predict incident hypertension in older adults?Metreleptin: first global approval.Current status of therapy in nonalcoholic Fatty liver disease.Lipodystrophy: pathophysiology and advances in treatment Leptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet.Therapeutic impact of leptin on diabetes, diabetic complications, and longevity in insulin-deficient diabetic mice Leptin replacement therapy for the treatment of non-HAART associated lipodystrophy syndromes: a meta-analysis into the effects of leptin on metabolic and hepatic endpoints.Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience Association of serum leptin levels with progression of diabetic kidney disease in patients with type 2 diabetes.Repositioning leptin as a therapy for Alzheimer's disease Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes.Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety.FOSL2 promotes leptin gene expression in human and mouse adipocytes.Seipin: from human disease to molecular mechanism Leptin in relation to the lipodystrophy-associated metabolic syndrome Functional magnetic resonance imaging analysis of food-related brain activity in patients with lipodystrophy undergoing leptin replacement therapy.Decrease in hepatic very-low-density lipoprotein-triglyceride secretion after weight loss is inversely associated with changes in circulating leptin.Leptin activates hepatic 5'-AMP-activated protein kinase through sympathetic nervous system and α1-adrenergic receptor: a potential mechanism for improvement of fatty liver in lipodystrophy by leptin Central leptin insufficiency syndrome: an interactive etiology for obesity, metabolic and neural diseases and for designing new therapeutic interventions.Lymphoma in acquired generalized lipodystrophy.A case for new therapy for diabetes, is it leptin?Leptin therapy, insulin sensitivity, and glucose homeostasis.Benefits of leptin therapy in HIV patients.Berardinelli-Seip syndrome: highlight of treatment challenge Leptin may enhance hepatic insulin sensitivity in children and women born small for gestational age.Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation.Intracellular lipid accumulation in liver and muscle and the insulin resistance syndrome.Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy Changes in insulin sensitivity during leptin replacement therapy in leptin-deficient patients.Selective leptin resistance revisited.Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment.The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia.

P2860

Q26781946-2D4E024D-8F29-4F3E-BFBF-324CE44BC6FA Q26859118-4B5ED64A-B47D-4BA0-8236-01DA356F0CF9 Q28087233-9E775CFE-1CEF-4A14-A73C-86B713FDDF45 Q28088325-F3191079-FC4E-4470-B46C-D4A1C181DF75 Q33602487-D8422E90-A66A-468C-BFA6-6A56E600850F Q33622272-8559D568-DD51-4131-AEC9-7DC889AFC3B8 Q33832051-7A01BF72-349B-44BA-BDDB-20AD6DE488A2 Q33936634-2EBF350B-C0C1-4305-AFD0-B0D74FA7A4C4 Q34348966-99E1FFA4-7D2D-4B2D-A914-B4FF9448B863 Q34408961-7A8B9CC5-0312-4605-BE66-907D5730150B Q35148915-B331358A-72F9-47D7-AF76-CC5E5EF5F2FA Q35174427-7B3880B0-4153-4996-AF85-C6DB692E0A78 Q35180084-4D82CBD7-59C8-4829-98F3-1D08A31468B2 Q35480563-254CB2B4-DDD5-4FE8-83C8-BC201A760659 Q35547148-3DAEBFC8-34A6-420C-880B-FC8E5FB531F2 Q35563693-BB7B5E4E-6B64-4472-826D-F1BBCD6AD09A Q35569809-58700045-41D8-42B1-94B3-8B2F630F98EC Q35578335-2D15D34D-A4EC-466E-8FD2-4067755144E4 Q35796963-143501E1-4C30-48E1-B38C-17DC797439AF Q35869668-05497879-00EA-45C9-B158-AAC044DFC00F Q35878661-47B63334-5846-4BD4-8875-100A88E39777 Q35958418-70D91907-241D-4480-9321-E0FB04CB156E Q36049195-4862777A-E541-49F5-9C3E-CE0EFBDFB13B Q36293562-AE98A455-5881-4D66-8AC1-043B4F1FECA5 Q36367336-E3F00648-B3A3-41F2-B121-7E16B25626F6 Q36418845-A8DB06F0-8C20-4549-A129-3EEE36675761 Q36464854-63438BE2-FC81-4643-BDDE-24E828267A81 Q36584738-67676024-7E5F-4FE9-AAFC-90B3474BE433 Q36700857-BAD59DA4-4294-45CB-AEE7-E343E7F8BF99 Q36700877-A95D9714-C200-4DC9-910B-52CBA9FF4D8D Q36700922-3359DBDF-19F5-4FEF-B4E0-16545BE491B6 Q36704607-94F7DD94-3DDA-4287-AF90-413AF68CD441 Q36924525-47F4D344-BF47-42CA-B366-2578B98B734B Q36962898-3971D8F7-5E73-440B-8A75-E1AAD7C0D62E Q37052532-B75889BC-4482-48C8-BAC9-98E0BA2F64E2 Q37062692-D10EB164-7F35-40F1-AD3A-55984971E554 Q37120226-8EF9CBE0-0BB8-4DAE-BD06-CC06D654ACEA Q37147129-11DCFDEF-770B-4DB3-9FA5-D805C61CC22F Q37149405-BBB27343-2A34-4CDD-B6F8-42D7F6C9AC7F Q37193194-28AD1EE5-E1E9-41F5-89CB-054475F80FDE

P2860

Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.

http://www.wikidata.org/entity/Q51485069

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Efficacy and safety of leptin- ...... ith generalized lipodystrophy.

@en

Efficacy and safety of leptin- ...... ith generalized lipodystrophy.

@nl

type

label

Efficacy and safety of leptin- ...... ith generalized lipodystrophy.

@en

Efficacy and safety of leptin- ...... ith generalized lipodystrophy.

@nl

prefLabel

Efficacy and safety of leptin- ...... ith generalized lipodystrophy.

@en

Efficacy and safety of leptin- ...... ith generalized lipodystrophy.

@nl

P1433

Q51485069-E480DD3C-FFE5-4A2D-A0D0-77EE53DF6503

P1476

Q51485069-7F6D8E40-FDBF-4AD4-8B78-007CE745F7BD

P2093

Q51485069-11E8D0A8-B513-4222-8714-4AC37B5BE5DC

Q51485069-24EE7AFD-B106-4D71-943D-B4F9EB86A555

Q51485069-39A5199F-9A77-400C-BB6B-A6D03C493D32

Q51485069-3E2A0A4E-D2AF-411C-8593-E39B49C4DC64

Q51485069-54E00A26-9F2A-4C9E-AA2A-615231A4E558

Q51485069-6C906DF1-7448-4B62-9E41-347FF3E39836

Q51485069-7BB0C160-B06C-4362-B549-04B4A7DF0EE8

Q51485069-9C5EF3C2-15C5-4F0C-BF81-F1519C5401E3

Q51485069-9DCAF825-9256-485A-A2D2-C187266AF978

Q51485069-E6BEE1F5-2996-4CD0-8ECF-C37731DFF064

P304

Q51485069-BCAB3D5F-F2E2-4A82-B234-5632DE6AB042

P31

Q51485069-2D13FE07-0BE7-442F-B44C-1AC07EA7A352

P356

Q51485069-B8FB9B5E-D5ED-4327-BDD0-F15041C66F94

P407

Q51485069-9029F469-4AD4-4742-80DC-086D715766FD

P433

Q51485069-7A7206E1-DAE6-44BE-BDAD-F6596F88BE69

P478

Q51485069-1293E0D6-BBBB-4323-96CC-100459870C7B

P50

Q51485069-B3C400BC-31FF-4182-805A-629971BDA3D5

P577

Q51485069-EBC52EDC-EB01-4335-833D-526D9E639D3C

P5875

Q51485069-26B002DF-1B19-47E3-BC79-CB810CCBC169

P698

Q51485069-57560C9F-55F9-4984-8AA2-E10515399E29

P921

Q51485069-6CC3E90F-C516-4C06-A90D-FE691652CA23

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Efficacy and safety of leptin- ...... with generalized lipodystrophy

@en

P2093

Alex M DePaoli

http://www.w3.org/2001/XMLSchema#string

Fumiko Miyanaga

http://www.w3.org/2001/XMLSchema#string

Hideki Chusho

http://www.w3.org/2001/XMLSchema#string

Hiroaki Masuzaki

http://www.w3.org/2001/XMLSchema#string

Kazuwa Nakao

http://www.w3.org/2001/XMLSchema#string

Ken Ebihara

http://www.w3.org/2001/XMLSchema#string

Kiminori Hosoda

http://www.w3.org/2001/XMLSchema#string

Masakazu Hirata

http://www.w3.org/2001/XMLSchema#string

Masanori Fukushima

http://www.w3.org/2001/XMLSchema#string

Nozomi Kobayashi

http://www.w3.org/2001/XMLSchema#string

P304

532-541

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2006-1546

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P50

Tatsuya Hayashi

P577

2006-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6679027

http://www.w3.org/2001/XMLSchema#string

P698

17118991

http://www.w3.org/2001/XMLSchema#string

P921